Psychosocial Treatment for Improving Chances of Survival in Women With Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
David Spiegel, Stanford University
ClinicalTrials.gov Identifier:
NCT00226928
First received: September 12, 2005
Last updated: December 2, 2013
Last verified: December 2013
  Purpose

This study will investigate the influence of psychosocial treatment on psychological outcomes and survival among women with metastatic or recurrent breast cancer.


Condition Intervention
Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer
Behavioral: Supportive-Expressive Group Therapy plus education
Behavioral: Education

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Psychosocial Treatment Effects on Cancer Survival

Resource links provided by NLM:


Further study details as provided by Stanford University:

Enrollment: 125
Study Completion Date: July 2005
Detailed Description:

The objective of this study is to investigate the influence of psychosocial treatment on psychological outcomes and survival among women with metastatic/recurrent breast cancer.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Women were eligible for the study if they had documented metastatic or recurrent breast cancer, were proficient enough in English to be able to complete questionnaires and participate in a support group, were living in the Greater San Francisco Bay Area, and had a Karnofsky score of at least 70%.19 Exclusion Criteria:

Women were excluded if they had any of the following risk factors: positive supraclavicular lymph nodes as the only metastatic lesion at the time of initial diagnosis; active non-breast cancers within the past 10 years; or other concurrent medical conditions likely to influence short-term survival. Basal cell or squamous cell carcinomas of the skin, in situ cancer of the cervix, or melanoma with a Breslow depth less than 0.76 mm were allowed.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00226928

Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: David Spiegel, M.D. Stanford University
  More Information

Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: David Spiegel, Jack, Lulu & Sam Willson Professor, Stanford University
ClinicalTrials.gov Identifier: NCT00226928     History of Changes
Other Study ID Numbers: R01 MH47226, R01MH047226, DAHBR HB-C
Study First Received: September 12, 2005
Last Updated: December 2, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on September 16, 2014